Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has added a new asset, 64/67Cu-SAR-trastuzumab, into its Targeted Copper Theranostic portfolio.
-
Latest News
Immunoglobulin sales drive a strong first half for CSL
February 11, 2025 -
Latest News
AusBiotech extends abstract deadline for April edition of Australasian Biotechnology Journal
February 11, 2025 -
Latest News
AdvanCell enters strategic collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025
-
Latest News Clarity expands pipeline in breast cancer with Cu-64/67 SAR-trastuzumab February 11, 2025
-
Latest News PYC Therapeutics to commence human clinical trials of PYC-003 for polycystic kidney disease February 11, 2025PYC Therapeutics (ASX:PYC) has announced that it has received all required regulatory approvals to commence human clinical trials of PYC-003.
-
Latest News US university joins Chimeric's CHM CDH17 clinical trial February 11, 2025Chimeric Therapeutics (ASX:CHM) has announced that the University of Chicago Medicine is now open to enrolling patients in the Phase 1/2 multi-centre clinical trial for the CHM CDH17 cell therapy.
-
Latest News Vaxxas appoints vaccine experts as it prepares for late-stage clinical trials February 6, 2025Clinical-stage company Vaxxas has announced the appointments of three respected vaccine experts as advisors to its product development and strategy team as it advances its novel high-density microarray patch (HD-MAP) vaccine technology towards later-stage clinical trials and commercialisation.
-
Latest News ImpediMed secures significant growth capital facility February 6, 2025Brisbane-based ImpediMed (ASX:IPD) has secured an agreement for a five-year US$15 million growth capital facility with SWK Funding LLC, a specialist finance company with a specific global healthcare sector focus.
-
Latest News AdAlta announces it will prioritise 'East to West' cellular immunotherapy strategy February 6, 2025AdAlta (ASX:1AD) has announced it will accelerate its 'East to West' cellular immunotherapy growth strategy by executing two non-binding term sheets to in-license clinical-stage CAR-T products, bringing total products in advanced due diligence to three.
-
Latest News Little Green Pharma completes Health House acquisition February 6, 2025Little Green Pharma (ASX:LGP) has completed the acquisition of HHI, the owner of the Health House medicinal cannabis distribution business.
-
Latest News Alterity Therapeutics announces positive trial results in Multiple System Atrophy January 30, 2025Alterity Therapeutics (ASX:ATH) has announced positive topline results from the ATH434-201 randomised, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy.
-
Latest News AusBiotech congratulates members recognised in Australia Day Honours January 30, 2025AusBiotech has celebrated the achievements of members recognised in this year's Australia Day Honours List.
-
Latest News Biome reports positive results on clinical development of BMB18 January 30, 2025Microbiome health company Biome Australia (ASX:BIO) has updated investors on the strain development program.
-
Latest News New link revealed between hypertension and the gut January 30, 2025According to Monash University researchers, the gut and two-cell regulators may pave the way to better high-blood-pressure drugs.
-
Latest News Anatara announces Australian patent granted for GaRP candidate January 30, 2025Anatara Lifesciences (ASX:ANR) has reported that it has received certification of the grant of a standard patent on 23 January for the GaRP product under the invention title of 'Gastrointestinal Health Composition'.
-
Latest News TGA approves CSL's locally discovered and developed biologic January 28, 2025“I realised we had something special when our lead scientist on this programme came into my office and showed me some data related to the screening they'd been doing," said Dr Andrew Nash, CSL’s chief scientific officer.
-
Latest News IDT updates investors, expecting a significant spike in revenue January 28, 2025Pharmaceutical manufacturer IDT Australia (ASX:IDT) has updated investors, reporting a significant rise in revenue for the final three months of the calendar year 2024.
-
Latest News Telix completes the acquisition of US-based RLS Radiopharmacies January 28, 2025Telix Pharmaceuticals (ASX:TLX) has completed the acquisition of RLS (RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network that distributes PET, SPECT, and therapeutic radiopharmaceuticals.
-
Latest News Zelira’s HOPE SPV secures fourth funding tranche to support FDA program January 28, 2025Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) has announced it has received the fourth tranche of US$681,000 of the US$3.25 million funding to support clinical trials for its proprietary and patent-protected HOPE 1 product.
-
Latest News Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial January 22, 2025Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial.
New Stories
-
AdvanCell enters strategic collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News -
AusBiotech extends abstract deadline for April edition of Australasian Biotechnology Journal
February 11, 2025 - - Latest News -
US university joins Chimeric's CHM CDH17 clinical trial
February 11, 2025 - - Latest News -
Immunoglobulin sales drive a strong first half for CSL
February 11, 2025 - - Latest News -
Clarity expands pipeline in breast cancer with Cu-64/67 SAR-trastuzumab
February 11, 2025 - - Latest News -
PYC Therapeutics to commence human clinical trials of PYC-003 for polycystic kidney disease
February 11, 2025 - - Latest News -
Vaxxas appoints vaccine experts as it prepares for late-stage clinical trials
February 6, 2025 - - Latest News